{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:38:32Z","timestamp":1783485512411,"version":"3.55.0"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>\n            Objective\u2003This article estimates the interaction between types of combined hormonal contraception (CHC) and factor V Leiden (FVL) mutation on the risk of venous thrombosis event (VTE).<\/jats:p><jats:p>\n            Subjects and Methods\u2003All premenopausal women with first incident VTE who were referred to our unit (Paris, France) between 2000 and 2009 were included in this case-only study. Differences in interactions by progestin type were assessed on a multiplicative scale, assuming the independence of genotype and prescription of type of CHC.<\/jats:p><jats:p>\n            Results\u2003Among 2,613 women with VTE, 15.9% had a FVL and 69% used CHC. The interaction between CHC use and presence of FVL on VTE risk was statistically significant (1.37, 1.06\u20131.77 95% confidence interval [CI]). This interaction appeared higher for drospirenone 1.99 (1.18\u20133.38 95% CI) (n\u2009=\u200998) or cyproterone acetate users 1.71 (1.20\u20132.45 95% CI) (n\u2009=\u2009326), but not significant for 1st or 2nd or norgestimate CHC users. The results were similar when excluding women with a family history of VTE or with provoked VTE. In this sub-group of women, these interactions appeared higher for third generation, cyproterone acetate and drospirenone CHC users as compared with 1st or 2nd or norgestimate CHC users (odds ratio [OR], 1.68 [1.04\u20132.70; 95% CI], 2.91 [1.71\u20134.95 95% CI], 3.22 [1.54\u20136.73 95% CI], respectively).<\/jats:p><jats:p>\n            Conclusion\u2003Our results show that the interaction between FVL and CHC use differ by progestin type, which is higher in CHC containing third-generation progestin, drospirenone or cyproterone acetate, compared with second generation. Further studies are needed to assess the cost-effectiveness of biological thrombophilia screening (FVL) when such prescription of CHC is planned.<\/jats:p>","DOI":"10.1055\/s-0038-1641152","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T18:51:13Z","timestamp":1522781473000},"page":"922-928","source":"Crossref","is-referenced-by-count":36,"title":["Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism"],"prefix":"10.1055","volume":"118","author":[{"given":"Justine","family":"Hugon-Rodin","sequence":"first","affiliation":[{"name":"Unity 1018 in Centre de recherche en \u00c9pid\u00e9miologie et Sant\u00e9 des Populations (CESP), University Paris-Saclay and Paris-Sud, INSERM, Villejuif, France"},{"name":"Gynecology Endocrinology Unit, H\u00f4pital Universitaire Paris-Centre, APHP, Paris, France"},{"name":"University Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Horellou","sequence":"first","affiliation":[{"name":"Hematology Biology Unit, H\u00f4pital Universitaire Paris-centre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Conard","sequence":"first","affiliation":[{"name":"Hematology Biology Unit, H\u00f4pital Universitaire Paris-centre, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gompel","sequence":"first","affiliation":[{"name":"Gynecology Endocrinology Unit, H\u00f4pital Universitaire Paris-Centre, APHP, Paris, France"},{"name":"University Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Plu-Bureau","sequence":"additional","affiliation":[{"name":"Gynecology Endocrinology Unit, H\u00f4pital Universitaire Paris-Centre, APHP, Paris, France"},{"name":"University Paris Descartes, Paris, France"},{"name":"Hematology Biology Unit, H\u00f4pital Universitaire Paris-centre, Paris, France"},{"name":"Equipe EPOPE, Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2018,4,3]]},"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0038-1641152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T18:31:24Z","timestamp":1527705084000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0038-1641152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":0,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2018,5,30]]},"published-print":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0038-1641152","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]}}}